Abstracts tagged "SLE and autoantibodies"

Abstract Number: 1092 • 2018 ACR/ARHP Annual Meeting
Immune Complex-Driven Neutrophil Activation and BAFF Production Promote B Cell Activation and Autoantibody Production in Human SLE
Andrew Vasconcellos¹, John Marken¹, Sladjana Skopelja-Gardner¹, Christian Lood² and Natalia V. Giltiay¹, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Division of Rheumatology, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: The production of anti-nuclear auto-antibodies (Ab) and the formation of immune complexes (IC) are hallmarks of Systemic Lupus Erythematosus (SLE). Enhanced neutrophil (PMN) activation…
Abstract Number: 1088 • 2016 ACR/ARHP Annual Meeting
Expansion of Transitional B Cells in SLE Patients Correlates with Increased Toll-like Receptor 7 Expression
Ting Wang^1,2, John Marken¹, Karen Cerosaletti³ and Natalia V. Giltiay¹, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA, Seattle, WA, ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China, Beijing, China, ³Translational Research Program Benaroya Research Institute at Virginia Mason, Seattle, WA, USA, Seattle, WA
Background/Purpose: B cell hyperactivation and autoantibody (auto-Ab) production are hallmarks of SLE. Auto-Abs, reactive to RNA-containing antigens are found in a fraction of SLE patients,…
Abstract Number: 2831 • 2016 ACR/ARHP Annual Meeting
Associations of BAFF and Anti-BAFF Autoantibodies with Disease Activity in Oriental Systemic Lupus Erythematosus
Hwee-Siew Howe¹, Bernard Thong², Kok Ooi Kong³, Hiok-Hee Chng², Tsui Yee Lian², Faith Chia², Karine Tay², Tang Ching Lau⁴, Weng Giap Law², Ee Tzun Koh⁵ and Bernard Pui Lam Leung^6,7, ¹Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, SINGAPORE, Singapore, ²Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, ., Singapore, ³Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ⁴Yong Loo Lin School of Medicine,, National University of Singapore, ., Singapore, ⁵Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, ., Singapore, ⁶Physiology, National University of Singapore, ., Singapore, ⁷Rheumatology, Allergy & Immunology, Tan Tock Seng Hospital, ., Singapore
Background/Purpose: B cell activating factor (BAFF) is implicated in the pathogenesis of systemic lupus erythematosus (SLE). A previous small scale study reported that endogenous neutralizing…
Abstract Number: 1626 • 2014 ACR/ARHP Annual Meeting
Autoantibodies Against High Mobility Group Box 1 (HMGB1) in Patients with SLE
Fleur Schaper¹, Gerda Horst¹, Daan van Beijeren Bergen en Henegouwen¹, Johan Bijzet¹, Karina de Leeuw¹, Alja Stel¹, Pieter C Limburg², Peter Heeringa³ and Johanna Westra¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: High mobility group box 1 (HMGB1) is a damage-associated molecular pattern and can be divided in three separate domains: the A Box, B Box…
Abstract Number: 1599 • 2013 ACR/ARHP Annual Meeting
High Proportion Of Intrathecal Ro52 SSA Antibodies In Neuropsychiatric Lupus Patients – Relations To Neuropsychiatric Manifestations
Johanna Estelius¹, Liisa Hopia², Vijole Dzikaite-Ottosson³, Magnus LA. Andersson⁴, Elisabet Svenungsson⁵ and Jon Lampa⁶, ¹Department of Medicine, Rheumatology Unit, Center for Molecular medicine (CMM), Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Centre for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden, ⁴Department of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Neuropsychiatric (NP) manifestations in Systemic Lupus Erythematosus (SLE) are often associated with significant impact on quality of life and work capability. The underlying mechanisms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].